Vis enkel innførsel

dc.contributor.authorPulczynski, Elisa J.
dc.contributor.authorKuittinen, Outi
dc.contributor.authorErlanson, Martin
dc.contributor.authorHagberg, Hans
dc.contributor.authorFosså, Alexander
dc.contributor.authorEriksson, Mikael
dc.contributor.authorNordström, Marie
dc.contributor.authorØstenstad, Bjørn
dc.contributor.authorFluge, Øystein
dc.contributor.authorLeppä, Sirpa
dc.contributor.authorFiirgaard, Bente
dc.contributor.authorBersvendsen, Hanne
dc.contributor.authorFagerli, Unn-Merete
dc.date.accessioned2019-11-22T08:26:54Z
dc.date.available2019-11-22T08:26:54Z
dc.date.created2015-07-07T15:00:09Z
dc.date.issued2015
dc.identifier.citationHaematologica. 2015, 100 (4), 534-540.nb_NO
dc.identifier.issn0390-6078
dc.identifier.urihttp://hdl.handle.net/11250/2629972
dc.description.abstractThe Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment. Patients aged 18–75 years were eligible. Thirty-nine patients aged 18–65 years and 27 patients aged 66–75 years were enrolled. The median age of the two age groups was 55 and 70 years, respectively. The overall response rate was 73.8% for the entire cohort: 69.9% in the younger and 80.8% in the elderly subgroup. With a median follow up of 22 months, the 2-year overall survival probability was 60.7% in patients aged 65 years or under and 55.6% in patients aged over 65 years (P=0.40). The estimated progression-free survival at two years was 33.1% (95%CI: 19.1%–47.9%) in patients aged under 65 years and 44.4% (95%CI: 25.6%–61.8%) in the elderly subgroup (P=0.74). Median duration of response was ten months in the younger subgroup, and not reached in the elderly patient subgroup (P=0.33). Four patients aged 64–75 years (6%) died from treatment-related complications. Survival in the two age groups was similar despite a de-escalation of induction treatment in patients aged over 65 years. Duration of response in elderly patients receiving maintenance temozolomide was longer than in the younger age subgroup. While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy. (clinicaltrials.gov identifier:01458730)nb_NO
dc.language.isoengnb_NO
dc.publisherFerrata Storti Foundationnb_NO
dc.titleSuccessful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Groupnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber534-540nb_NO
dc.source.volume100nb_NO
dc.source.journalHaematologicanb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.3324/haematol.2014.108472
dc.identifier.cristin1252849
dc.description.localcode© 2015 Ferrata Storti Foundation.This is an open-access paper.nb_NO
cristin.unitcode1920,12,0,0
cristin.unitcode194,65,15,0
cristin.unitnameKreftklinikken
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel